"10.1371_journal.pone.0055435","plos one","2013-03-11T00:00:00Z","Alessandra Vitelli; Mary R Quirion; Chia-Yun Lo; Julia A Misplon; Agnieszka K Grabowska; Angiolo Pierantoni; Virginia Ammendola; Graeme E Price; Mark R Soboleski; Riccardo Cortese; Stefano Colloca; Alfredo Nicosia; Suzanne L Epstein","Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America; Okairòs, Rome, Italy; Centro di Ingegneria Genetica e Biotecnologia Avanzate (CEINGE), Naples, Italy; Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy","Conceived and designed the experiments: AN SLE AV MRQ C-YL JAM GEP. Performed the experiments: AV MRQ C-YL JAM GEP MRS AP AKG. Analyzed the data: AV MRQ C-YL JAM GEP MRS SLE AN. Contributed reagents/materials/analysis tools: AKG AP VA SC RC. Wrote the paper: SLE GEP AV MRQ C-YL JAM RC.","The authors have the following interests: Authors from Okairòs are employees of and/or shareholders in Okairòs, which is developing vectored vaccines for malaria and other diseases. Okairòs is developing adenovirus based vaccines for influenza. This research was carried out under a collaborative agreement between CBER, FDA and Okairòs. There are no other patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Alessandra Vitelli","AV",13,TRUE,7,8,8,7,TRUE,TRUE,FALSE,0,NA,FALSE
